Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Makes Policy Waves With Pullback Of Longstanding TENS Coverage

This article was originally published in The Gray Sheet

Executive Summary

The new finalized coverage policy for transcutaneous electrical nerve stimulation for treating chronic back pain is a rare decision by the agency to reverse coverage on an established technology, and is a new direction for the coverage-with-evidence-development program, observers say.

You may also be interested in...

Medtech Tools To Help Address Opioid Crisis Face Reimbursement Challenges

A wide variety of devices that could either serve as pain-relief substitutes for opioids, help manage opioid addictions or tackle distribution issues with the overly prescribed medications are facing reimbursement challenges at the US Centers for Medicare and Medicaid Services.

New Coverage-With-Evidence-Development Guidance In The Works Following MedCAC Meeting

The Medicare Evidence Development & Coverage Advisory Committee was charged May 16 with helping CMS better define the evidence threshold under which the agency should or should not pursue a coverage- with-evidence-development policy.

Groups Pained By CMS’ Use Of Coverage With Evidence Development In TENS Proposal

A recent Medicare coverage proposal for transcutaneous electrical nerve stimulation for chronic low-back pain is an unprecedented application of CED to turn back coverage of an established treatment, numerous parties tell CMS.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts